N-(Indan-2-yl)-hydrazin | 45894-21-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: N-(Indan-2-yl)-hydrazin
• 英文别名: 2,3-dihydro-1H-inden-2-ylhydrazine
• CAS: 45894-21-1
• 化学式: C₉H₁₂N₂
• 分子量: 148.208
• InChiKey: IEHXIYQFEGQZIJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2928000090

反应信息

• 作为反应物：
  描述：

  丙烯腈 、 N-(Indan-2-yl)-hydrazin 在 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 生成 3-[1-(2-indanyl)hydrazino]propanenitrile
  参考文献：
  名称：

  3-[1-(2-Benzoxazolyl)hydrazino]propanenitrile derivatives: inhibitors of immune complex induced inflammation

  摘要：

  3-[1-(2-Benzoxazolyl)hydrazino]propanenitrile derivatives were evaluated in the dermal and pleural reverse passive Arthus reactions in the rat. In the pleural test these compounds were effective in reducing exudate volume and accumulation of white blood cells. This pattern of activity was similar to that of hydrocortisone and different from that of indomethacin. The structural requirements for inhibiting the Arthus reactions were studied by systematic chemical modification of 1. These structure-activity relationship studies revealed that nitrogen 1' of the hydrazino group is essential for activity and must be electron rich, whereas chemical modifications of other sites of 1 had only a modest effect on activity.

  DOI：

  10.1021/jm00117a010
• 作为产物：
  描述：

  2-氨基茚 在 盐酸 、 tin(ll) chloride 、 sodium nitrite 作用下， 生成 N-(Indan-2-yl)-hydrazin
  参考文献：
  名称：

  3-[1-(2-Benzoxazolyl)hydrazino]propanenitrile derivatives: inhibitors of immune complex induced inflammation

  摘要：

  3-[1-(2-Benzoxazolyl)hydrazino]propanenitrile derivatives were evaluated in the dermal and pleural reverse passive Arthus reactions in the rat. In the pleural test these compounds were effective in reducing exudate volume and accumulation of white blood cells. This pattern of activity was similar to that of hydrocortisone and different from that of indomethacin. The structural requirements for inhibiting the Arthus reactions were studied by systematic chemical modification of 1. These structure-activity relationship studies revealed that nitrogen 1' of the hydrazino group is essential for activity and must be electron rich, whereas chemical modifications of other sites of 1 had only a modest effect on activity.

  DOI：

  10.1021/jm00117a010

文献信息

• [EN] IMIDAZOPYRIDINE COMPOUNDS<br/>[FR] COMPOSÉS IMIDAZOPYRIDINES
  申请人：PROXIMAGEN LTD

  公开号：WO2010064020A1

  公开（公告）日：2010-06-10

  The invention relates to compounds of formula (I): and their pharmaceutically acceptable salts and solvates, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.

  这项发明涉及式(I)的化合物及其药学上可接受的盐和溶剂化合物，这些化合物是SSAO活性的抑制剂。该发明还涉及包含这些化合物的药物组合物，以及利用这些化合物治疗或预防抑制SSAO活性有益的医疗状况，如炎症性疾病和免疫紊乱。
• [EN] IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS<br/>[FR] DÉRIVÉS D'IMIDAZO[4,5-C]PYRIDINE ET DE PYRROLO[2,3-C]PYRIDINE EN TANT QU'INHIBITEURS SSAO
  申请人：PROXIMAGEN LTD

  公开号：WO2014140592A1

  公开（公告）日：2014-09-18

  The compounds of formula (I) are inhibitors of semicarbazide- sensitive amine oxidase (SSAO) activity useful in the treatment of inflammation, an inflammatory disease, an immune or an autoimmune disorder, or inhibition of tumour growth.

  式(I)的化合物是半羧肼敏感胺氧化酶（SSAO）活性的抑制剂，可用于治疗炎症、炎症性疾病、免疫或自身免疫性疾病，或抑制肿瘤生长。
• [EN] VAP-1 INHIBITORS FOR TREATING PAIN<br/>[FR] INHIBITEURS DE VAP-1 POUR LE TRAITEMENT DE LA DOULEUR
  申请人：PROXIMAGEN LTD

  公开号：WO2017098236A1

  公开（公告）日：2017-06-15

  This invention relates to the use of inhibitors of VAP-1/SSAO activity, and pharmaceutical compositions comprising the same, for the treatment of pain; and to a combined preparation comprising an inhibitor of VAP-1/SSAO activity and a steroid, and the use of the combined preparation in medicine, particularly for treatment of pain.

  这项发明涉及使用VAP-1/SSAO活性抑制剂以及包含相同成分的药物组合物，用于治疗疼痛；以及包含VAP-1/SSAO活性抑制剂和类固醇的联合制剂，以及在医学中使用该联合制剂，特别是用于治疗疼痛。
• New Enzyme Inhibitor Compounds
  申请人：Evans David

  公开号：US20130102587A1

  公开（公告）日：2013-04-25

  Disclosed are compounds which inhibit SSAO enzyme activity. Also disclosed are pharmaceutical compositions comprising these compounds and the use of these compounds in the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases, immune disorders and the inhibition of tumour growth.

  揭示了抑制SSAO酶活性的化合物。还披露了包含这些化合物的药物组合物，以及在治疗或预防抑制SSAO活性有益的医疗状况中使用这些化合物，如炎症性疾病、免疫紊乱和抑制肿瘤生长。
• NEW COMPOUNDS
  申请人：PROXIMAGEN LIMITED

  公开号：US20160024080A1

  公开（公告）日：2016-01-28

  The compound of formula (I) are inhibitors of SSAO activity (Formula (I)) wherein the terms Y, Z, W, R 1 and R 2 are defined in the claims.

  化合物的化学式（I）是SSAO活性的抑制剂（化学式（I）），其中术语Y、Z、W、R1和R2在专利权要求中有定义。